Novo Nordisk A/S
XMUN:NOV

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
XMUN:NOV
Watchlist
Price: 52.05 EUR 4.95% Market Closed
Market Cap: 176.2B EUR
Section:
 

Relative Value

The Relative Value of one NOV stock under the Base Case scenario is hidden EUR. Compared to the current market price of 52.05 EUR, Novo Nordisk A/S is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NOV Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

5.4
P/S
P/S
Price to Sales
5.4
vs History
88
vs Industry
18
Median 3Y
10.9
Median 5Y
9.9
Industry
2.7
Forward
5.4
More Details
16.3
P/E
P/E
Price to Earnings
16.3
vs History
88
vs Industry
21
Median 3Y
34.9
Median 5Y
29.4
Industry
21.6
Forward
16.1
More Details
13.7
P/OCF
P/OCF
Price to OCF
13.7
vs History
90
vs Industry
23
Median 3Y
25.1
Median 5Y
23.1
Industry
16.9
More Details
17.2
P/FCFE
P/FCFE
Price to FCFE
17.2
vs History
84
vs Industry
24
Median 3Y
32.9
Median 5Y
24.5
Industry
22.9
More Details
10
P/B
P/B
Price to Book Value
10
vs History
88
vs Industry
3
Median 3Y
24.2
Median 5Y
20.2
Industry
2.3
More Details
5.5
EV/S
EV/S
Enterprise Value to Sales
5.5
vs History
92
vs Industry
16
Median 3Y
11
Median 5Y
9.9
Industry
3
Forward
5.6
More Details
6.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.8
vs History
88
vs Industry
22
Median 3Y
13.1
Median 5Y
11.9
Industry
5.6
More Details
11.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
11.3
vs History
88
vs Industry
25
Median 3Y
23.3
Median 5Y
21.4
Industry
13.4
Forward
11.6
More Details
13.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
13.2
vs History
88
vs Industry
25
Median 3Y
25.6
Median 5Y
23.4
Industry
16.7
Forward
13.4
More Details
14.1
EV/OCF
EV/OCF
Enterprise Value to OCF
14.1
vs History
88
vs Industry
23
Median 3Y
25
Median 5Y
23.1
Industry
16.1
More Details
28.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
28.7
vs History
63
vs Industry
15
Median 3Y
33.1
Median 5Y
29.7
Industry
18.9
More Details
3.8
EV/IC
EV/IC
Enterprise Value to IC
3.8
vs History
90
vs Industry
13
Median 3Y
9.6
Median 5Y
8.7
Industry
2
More Details

Multiples Across Competitors

NOV Competitors Multiples
Novo Nordisk A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Novo Nordisk A/S
XMUN:NOV
1.7T EUR 5.4 16.3 11.3 13.2
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.6 36.7 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
491.8B USD 5.3 19.6 16 20.8
CH
Roche Holding AG
SIX:ROG
271.4B CHF 4.4 28.8 12.2 14.3
UK
AstraZeneca PLC
LSE:AZN
220.4B GBP 5.1 31.4 109 159.5
US
Merck & Co Inc
NYSE:MRK
274.9B USD 4.3 14.4 10.2 12.1
CH
Novartis AG
SIX:NOVN
218.8B CHF 4.9 19 12 15.5
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.9B USD 2.3 14.7 7.5 10.2
FR
Sanofi SA
PAR:SAN
102.8B EUR 1.5 7.4 6.8 6.8
P/E Multiple
Earnings Growth PEG
DK
Novo Nordisk A/S
XMUN:NOV
Average P/E: 22.9
16.3
3%
5.4
US
Eli Lilly and Co
NYSE:LLY
54.6
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.4
15%
1
CH
Novartis AG
SIX:NOVN
19
17%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
FR
Sanofi SA
PAR:SAN
7.4
26%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Novo Nordisk A/S
XMUN:NOV
Average EV/EBITDA: 400.6
11.3
1%
11.3
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
109
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
FR
Sanofi SA
PAR:SAN
6.8
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Novo Nordisk A/S
XMUN:NOV
Average EV/EBIT: 1 713
13.2
0%
N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.3
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.5
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.1
8%
1.5
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5
FR
Sanofi SA
PAR:SAN
6.8
15%
0.5

See Also

Summary
NOV intrinsic value, competitors valuation, and company profile.
DCF Valuation
NOV stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NOV stock valuation using valuation multiples.
Wall Street Estimates
NOV price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NOV stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 308,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.